Melinta Therapeutics, Inc. (MLNT) EPS Estimated At $-2.72

Analysts expect Melinta Therapeutics, Inc. (NASDAQ:MLNT) to report $-2.72 EPS on May, 9 after the close.They anticipate $2.03 EPS change or 42.74 % from last quarter’s $-4.75 EPS. After having $-1.93 EPS previously, Melinta Therapeutics, Inc.’s analysts see 40.93 % EPS growth. The stock increased 0.22% or $0.01 during the last trading session, reaching $4.51. About 79,485 shares traded. Melinta Therapeutics, Inc. (NASDAQ:MLNT) has declined 92.23% since May 8, 2018 and is downtrending. It has underperformed by 96.60% the S&P500.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. The company has market cap of $53.13 million. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. It currently has negative earnings. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013.

More notable recent Melinta Therapeutics, Inc. (NASDAQ:MLNT) news were published by: which released: “Melinta Therapeutics Reports Third Quarter 2018 Financial Results – GlobeNewswire” on November 07, 2018, also with their article: “58 Biggest Movers From Yesterday – Benzinga” published on April 02, 2019, published: “Melinta Therapeutics, Inc. (MLNT) Reports Q4 Loss, Tops Revenue Estimates – Nasdaq” on March 13, 2019. More interesting news about Melinta Therapeutics, Inc. (NASDAQ:MLNT) were released by: and their article: “Melinta Therapeutics to Present at Upcoming Investor Conferences – GlobeNewswire” published on September 25, 2018 as well as‘s news article titled: “Melinta up 11% premarket on positive delafloxacin data – Seeking Alpha” with publication date: October 29, 2018.

Melinta Therapeutics, Inc. (NASDAQ:MLNT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.